Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:CORT
- CUSIP: 21835210
- Web: www.corcept.com
Capitalization:- Market Cap: $1.39 billion
- Outstanding Shares: 113,187,000
Average Prices:- 50 Day Moving Avg: $10.38
- 200 Day Moving Avg: $9.17
- 52 Week Range: $4.95 - $12.40
P/E:- Trailing P/E Ratio: 112.75
- Foreward P/E Ratio: 24.10
- P/E Growth: 0.83
Sales & Book Value:- Annual Revenue: $92.86 million
- Price / Sales: 14.98
- Book Value: $0.44 per share
- Price / Book: 27.93
Profitability:- EBIDTA: $14.4 million
- Net Margins: 6.21%
- Return on Equity: 28.11%
- Return on Assets: 11.96%
Debt:- Current Ratio: 1.89%
- Quick Ratio: 1.81%
Misc:- Average Volume: 1.04 million shs.
- Beta: 1.72
- Short Ratio: 6.14
Frequently Asked Questions for Corcept Therapeutics Incorporated (NASDAQ:CORT)
What is Corcept Therapeutics Incorporated's stock symbol?
Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics Incorporated's earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Monday, May, 1st. The company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.03 by $0.01. The business had revenue of $27.60 million for the quarter, compared to analyst estimates of $25.53 million. Corcept Therapeutics Incorporated had a net margin of 6.21% and a return on equity of 28.11%. The business's revenue was up 71.9% compared to the same quarter last year. View Corcept Therapeutics Incorporated's Earnings History.
When will Corcept Therapeutics Incorporated make its next earnings announcement?
Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?
4 brokerages have issued twelve-month target prices for Corcept Therapeutics Incorporated's stock. Their forecasts range from $7.00 to $18.00. On average, they anticipate Corcept Therapeutics Incorporated's stock price to reach $12.75 in the next twelve months. View Analyst Ratings for Corcept Therapeutics Incorporated.
Are investors shorting Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 6,325,479 shares, an increase of 5.7% from the March 31st total of 5,985,264 shares. Based on an average trading volume of 728,448 shares, the days-to-cover ratio is presently 8.7 days.
Who are some of Corcept Therapeutics Incorporated's key competitors?
Some companies that are related to Corcept Therapeutics Incorporated include Intrexon Corp (XON), SAGE Therapeutics (SAGE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), Clovis Oncology (CLVS), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Axovant Sciences Ltd (AXON), Portola Pharmaceuticals (PTLA), Theravance Biopharma (TBPH), Prothena Co. PLC (PRTA), FibroGen (FGEN), Cambrex (CBM), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Lexicon Pharmaceuticals (LXRX) and Radius Health (RDUS).
Who are Corcept Therapeutics Incorporated's key executives?
Corcept Therapeutics Incorporated's management team includes the folowing people:
- James N. Wilson, Chairman of the Board
- Joseph K. Belanoff M.D., President, Chief Executive Officer, Director
- Gary Charles Robb, Chief Financial Officer, Chief Accounting Officer, Secretary
- Renee D. Gala, Director
- Len L. Baker Jr., Independent Director
- Daniel Mark Bradbury, Independent Director
- Joseph C. Cook Jr., Independent Director
- Patrick G. Enright, Independent Director
Who owns Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (6.93%),
LONGITUDE CAPITAL PARTNERS, LLC
(5.70%), Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (1.64%), State Street Corp (1.42%) and Morgan Stanley (1.16%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright and Steven Lo. View Institutional Ownership Trends for Corcept Therapeutics Incorporated.
Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Ingalls & Snyder LLC, Menta Capital LLC, EAM Investors LLC, Russell Investments Group Ltd., Oxford Asset Management, Credit Suisse AG and Public Employees Retirement Association of Colorado. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include James N Wilson, Joseph K Belanoff and Patrick G Enright. View Insider Buying and Selling for Corcept Therapeutics Incorporated.
Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Bank of New York Mellon Corp, Driehaus Capital Management LLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Renaissance Technologies LLC, State Street Corp and Bogle Investment Management L P DE. Company insiders that have bought Corcept Therapeutics Incorporated stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics Incorporated.
How do I buy Corcept Therapeutics Incorporated stock?
Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics Incorporated's stock price today?
One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $12.29.
MarketBeat Community Rating for Corcept Therapeutics Incorporated (NASDAQ CORT)MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)Earnings History by Quarter for Corcept Therapeutics Incorporated (NASDAQ CORT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/31/2017 | | | | | | | | |
| 5/1/2017 | Q1 2017 | $0.03 | $0.04 | $25.53 million | $27.60 million | View | Listen |  |
| 3/6/2017 | Q4 2016 | $0.04 | $0.04 | $23.85 million | $23.81 million | View | N/A | |
| 11/1/2016 | Q316 | $0.01 | $0.02 | $21.24 million | $21.70 million | View | N/A | |
| 1/28/2016 | Q415 | ($0.02) | $0.01 | $15.50 million | $15.00 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.02) | ($0.01) | $13.90 million | $13.30 million | View | N/A | |
| 8/5/2015 | Q215 | ($0.04) | ($0.02) | $11.67 million | $11.96 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.04) | ($0.05) | $10.50 million | $10.10 million | View | N/A | |
| 3/4/2015 | Q414 | ($0.06) | ($0.03) | $9.10 million | $9.01 million | View | N/A | |
| 11/4/2014 | Q214 | ($0.07) | ($0.05) | $7.62 million | $7.28 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.10) | ($0.13) | $5.01 million | $4.41 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.10) | ($0.11) | $4.01 million | $4.10 million | View | N/A | |
| 1/30/2014 | Q4 | ($0.12) | ($0.10) | | | View | N/A | |
| 11/7/2013 | Q313 | ($0.12) | ($0.08) | $2.70 million | $2.60 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.11) | ($0.10) | $2.72 million | $1.90 million | View | N/A | |
| 5/2/2013 | Q1 2013 | ($0.09) | ($0.10) | $2.48 million | $1.72 million | View | N/A | |
| 3/7/2013 | Q4 2012 | ($0.09) | ($0.09) | $1.50 million | $1.38 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.51 EPS
Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Corcept Therapeutics Incorporated (NASDAQ:CORT)Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 43.57%
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/4/2017 | Gary Charles Robb | CFO | Buy | 5,600 | $9.75 | $54,600.00 | |
| 3/16/2017 | Patrick G. Enright | Director | Sell | 269,955 | $9.94 | $2,683,352.70 | |
| 3/15/2017 | Patrick G Enright | Director | Sell | 600,000 | $10.15 | $6,090,000.00 | |
| 3/8/2017 | Patrick G Enright | Director | Sell | 750,000 | $9.75 | $7,312,500.00 | |
| 2/27/2017 | Patrick G Enright | Director | Sell | 2,500,000 | $8.81 | $22,025,000.00 | |
| 11/25/2016 | Patrick G Enright | Director | Sell | 36,941 | $9.34 | $345,028.94 | |
| 11/21/2016 | Patrick G Enright | Director | Sell | 544,100 | $9.56 | $5,201,596.00 | |
| 11/16/2016 | Patrick G Enright | Director | Sell | 174,847 | $9.55 | $1,669,788.85 | |
| 11/11/2016 | James N Wilson | Director | Sell | 158,812 | $8.51 | $1,351,490.12 | |
| 11/11/2016 | Joseph K Belanoff | Insider | Sell | 500,000 | $8.98 | $4,490,000.00 | |
| 11/7/2016 | Joseph K Belanoff | CEO | Sell | 500,000 | $8.31 | $4,155,000.00 | |
| 5/10/2016 | G Leonard Baker Jr | Director | Buy | 100,000 | $4.88 | $488,000.00 | |
| 1/6/2016 | James N Wilson | Director | Sell | 1,188 | $4.90 | $5,821.20 | |
| 12/10/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.85 | $97,000.00 | |
| 11/24/2015 | Daniel Bradbury | Director | Sell | 40,000 | $5.00 | $200,000.00 | |
| 11/12/2015 | James N Wilson | Director | Sell | 20,000 | $4.90 | $98,000.00 | |
| 11/2/2015 | Steven Lo | VP | Sell | 12,500 | $4.00 | $50,000.00 | |
| 10/13/2015 | Steven Lo | VP | Sell | 53,033 | $3.82 | $202,586.06 | |
| 10/7/2015 | Steven Lo | VP | Sell | 5,300 | $4.00 | $21,200.00 | |
| 10/6/2015 | Steven Lo | VP | Sell | 50,000 | $3.76 | $188,000.00 | |
| 9/16/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.96 | $99,200.00 | |
| 9/1/2015 | James N Wilson | Director | Sell | 10,000 | $4.90 | $49,000.00 | |
| 8/27/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.76 | $95,200.00 | |
| 7/21/2015 | Daniel Bradbury | Director | Sell | 10,000 | $4.98 | $49,800.00 | |
| 7/20/2015 | Daniel Bradbury | Director | Sell | 10,000 | $5.32 | $53,200.00 | |
| 7/8/2015 | David L Mahoney | Director | Sell | 33,828 | $5.74 | $194,172.72 | |
| 7/1/2015 | James N Wilson | Director | Sell | 10,000 | $6.06 | $60,600.00 | |
| 6/24/2015 | Daniel Bradbury | Director | Sell | 20,000 | $6.75 | $135,000.00 | |
| 6/23/2015 | Daniel Bradbury | Director | Sell | 10,000 | $6.92 | $69,200.00 | |
| 6/2/2015 | James N Wilson | Director | Sell | 10,000 | $6.13 | $61,300.00 | |
| 3/24/2015 | Patrick G Enright | Director | Sell | 1,089,745 | $5.75 | $6,266,033.75 | |
| 3/19/2015 | Joseph C Cook Jr | Director | Sell | 77,200 | $5.22 | $402,984.00 | |
| 6/11/2014 | G Leonard Baker Jr | Director | Buy | 103,386 | $2.32 | $239,855.52 | |
| 5/13/2014 | Joseph Cook, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | |
| 5/12/2014 | Daniel Bradbury | Director | Buy | 138,925 | $1.80 | $250,065.00 | |
| 5/9/2014 | G Leonard Baker, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | |
| 5/2/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.11 | $1,027,500.00 | |
| 4/1/2014 | Patrick Enright | Director | Sell | 250,000 | $4.28 | $1,070,000.00 | |
| 3/7/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.00 | $1,000,000.00 | |
| 3/14/2013 | Joseph L Turner | Director | Buy | 10,000 | $2.01 | $20,100.00 | |
| 12/5/2012 | G Leonard Baker Jr | Director | Buy | 87,131 | $1.46 | $127,211.26 | |
| 11/23/2012 | Daniel Bradbury | Director | Buy | 179,000 | $1.39 | $248,810.00 | |
| 11/7/2012 | G Leonard Baker Jr | Director | Buy | 300,000 | $1.83 | $549,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ:CORT)
| Source: |
|
| Date | Headline |
|---|
 | Corcept Therapeutics Incorporated (CORT) Upgraded at TheStreet
www.americanbankingnews.com - May 25 at 2:42 PM |
 | Pharma Stock With Triple-Digit Growth Forming Blotchy Base
finance.yahoo.com - May 24 at 12:40 PM |
| Corcept Therapeutics Incorporated (CORT)
finance.yahoo.com - May 19 at 8:37 AM |
| ETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017
finance.yahoo.com - May 18 at 4:21 PM |
| Corcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - May 15 at 2:34 PM |
| Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate
finance.yahoo.com - May 12 at 4:57 PM |
| Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May 10, 2017
finance.yahoo.com - May 10 at 4:36 PM |
| Corcept Therapeutics Incorporated (CORT) CFO Gary Charles Robb Acquires 5,600 Shares
www.americanbankingnews.com - May 8 at 8:22 PM |
| Zacks Investment Research Downgrades Corcept Therapeutics Incorporated (CORT) to Hold
www.americanbankingnews.com - May 8 at 4:16 PM |
| Corcept Therapeutics Incorporated (CORT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 5 at 11:38 AM |
| Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress
finance.yahoo.com - May 4 at 4:34 PM |
| TheStreet Downgrades Corcept Therapeutics Incorporated (CORT) to C+
www.americanbankingnews.com - May 3 at 5:56 PM |
| Edited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT
finance.yahoo.com - May 3 at 4:24 PM |
| Corcept Therapeutics Announces First Quarter 2017 Financial ... - Yahoo Finance
finance.yahoo.com - May 3 at 8:43 AM |
| Favorable News Coverage Somewhat Likely to Affect Corcept Therapeutics (CORT) Share Price
www.americanbankingnews.com - May 3 at 1:01 AM |
| Corcept posts 1Q profit
finance.yahoo.com - May 2 at 7:34 PM |
| Corcept Therapeutics Incorporated (CORT) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 1:03 PM |
| Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call
finance.yahoo.com - May 1 at 4:24 PM |
| Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
finance.yahoo.com - May 1 at 4:24 PM |
| Corcept Therapeutics Incorporated (CORT) Short Interest Update
www.americanbankingnews.com - April 29 at 11:56 PM |
| Corcept Therapeutics (CORT) Receiving Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 8:28 AM |
| Corcept Therapeutics Incorporated (CORT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:17 AM |
| Somewhat Positive Media Coverage Very Likely to Affect Corcept Therapeutics (CORT) Share Price
www.americanbankingnews.com - April 25 at 5:12 PM |
| Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : April 25, 2017
finance.yahoo.com - April 25 at 4:13 PM |
| Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
finance.yahoo.com - April 24 at 4:20 PM |
| Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April 24, 2017
finance.yahoo.com - April 24 at 9:27 AM |
| Here's Why Corecept Therapeutics Incorporated Had a Rough Day
finance.yahoo.com - April 21 at 9:32 PM |
 | Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
www.zacks.com - April 20 at 4:35 PM |
| Corcept Therapeutics (CORT) Receives News Impact Score of 0.56
www.americanbankingnews.com - April 20 at 11:53 AM |
| Corcept Therapeutics (CORT) Earns Daily Coverage Optimism Score of -0.22
www.americanbankingnews.com - April 14 at 7:54 AM |
| Corcept Therapeutics Incorporated (CORT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 10 at 11:31 AM |
| Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 7 at 9:07 AM |
| Corcept (CORT) Strives to Commercialize Key Drug Korlym
www.zacks.com - March 29 at 4:54 PM |
 | First Week of November 17th Options Trading For Corcept Therapeutics (CORT)
www.thestreet.com - March 21 at 4:44 PM |
| Insider Selling: Corcept Therapeutics Incorporated (CORT) Director Sells 269,955 Shares of Stock
www.americanbankingnews.com - March 20 at 7:28 PM |
| Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics
finance.yahoo.com - March 17 at 3:53 PM |
| Corcept Therapeutics Incorporated (CORT) Receives Consensus Recommendation of “Hold” from Analysts
www.americanbankingnews.com - March 15 at 1:30 PM |
| Patrick G. Enright Sells 750,000 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - March 10 at 6:18 PM |
 | CORCEPT THERAPEUTICS INC Financials
us.rd.yahoo.com - March 10 at 5:30 PM |
| Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance
us.rd.yahoo.com - March 6 at 10:28 AM |
| CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure
us.rd.yahoo.com - March 6 at 10:27 AM |
| CORT Crosses Above Average Analyst Target
www.thestreet.com - February 27 at 4:13 PM |
| CORCEPT THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financi
biz.yahoo.com - February 13 at 5:06 PM |
 | Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy - Benzinga
www.benzinga.com - February 2 at 9:52 PM |
| Coverage initiated on Corcept Therapeutics by Ladenburg Thalmann
finance.yahoo.com - February 2 at 4:49 PM |
| Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT
finance.yahoo.com - January 31 at 4:54 PM |
| Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance
us.rd.yahoo.com - January 30 at 5:17 PM |
| Preliminary Q4 2016 Corcept Therapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - January 30 at 7:35 AM |
 | Research Reports Coverage on Biotech Stocks -- PharmAthene, Corcept Therapeutics, Navidea Biopharma, and Inotek Pharma
www.bizjournals.com - January 25 at 5:36 PM |
| Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call
finance.yahoo.com - January 23 at 4:44 PM |
Corcept Therapeutics Incorporated (CORT) Chart for Monday, May, 29, 2017
